Advocacy intelligence hub — real-time data for patient organizations
Hospices Civils de Lyon — NA
Biocodex — PHASE3
treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs2
Oxlumo
(LUMASIRAN)Orphan drugAlnylam Pharmaceuticals, Inc.
12.1 Mechanism of Action Lumasiran reduces levels of glycolate oxidase (GO) enzyme by targeting the hydroxyacid oxidase 1 ( HAO1 ) messenger ribonucle...
Rivfloza
(NEDOSIRAN)Orphan drugstandardNovo Nordisk
12.1 Mechanism of Action Nedosiran is a double-stranded siRNA, conjugated to GalNAc aminosugar residues. After subcutaneous administration, the GalNAc...
Bernd Hoppe, MD PhD
Universitätsklinikum Bonn, Dept of Paediatric Nephrology
Gesa Schalk, MD
KindernierenZentrum, Bonn, Germany
Dawn Milliner, MD, M.D
Mayo Clinic
📍 ROCHESTER, MN
Verity Rawson
Dicerna, A Novo Nordisk Company
Verity Rawson, MB.CHB
Dicerna, A Novo Nordisk Company
📍 San Francisco, California
David Goldfarb, MD
NYU Langone Health